Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Handheld diagnostics specialist genedrive confirms award of £600,000 grant

The money will be used to help fund the development of a disposable centrifuge-free plasma separation device
centrifuge
It is hoped the new device will be able to separate plasma without the using a centrifuge (pictured).

Handheld diagnostics specialist genedrive plc (LON:GDR) has confirmed it and its partners have been formally awarded a £600,000 grant from Innovate UK, a body which supports technology and growth businesses.

The money will be used to help fund the development of a disposable, centrifuge-free plasma separation device.

The collaboration with NHS Tayside and the University of Dundee is designed to create companion 'kit' that can be used alongside genedrive’s Hepatitis C (HCV) diagnostic “closer to a point of care setting”.

“This has the opportunity to be a very novel and impactful project and we are delighted that Innovate UK has chosen to support us,” said chief executive David Budd. 

“This device will aim to improve the applicability of the Genedrive HCV assay for closer to patient settings and would be a significant step forward in positioning the test for true decentralised diagnostics.

“Further, the device is anticipated to be independent from the Genedrive platform, opening the opportunity for other diagnostic instruments that need plasma as a starting point for blood borne viral testing."

The company said it will account for its £484,000 share of the funding as income, matched to costs incurred over the periods to 30 June 2018 and 2019.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use